High-concentration cannabis products are sending more young children to the hospital

A review found that pediatric cannabis hospitalizations are increasingly caused by high-concentration products like edibles and vaping fluid, causing sedation and respiratory depression in toddlers, while chronic use in adolescents leads to cognitive changes and hyperemesis.

Blohm, Eike et al.·Current opinion in pediatrics·2019·Moderate EvidenceReview
RTHC-01950ReviewModerate Evidence2019RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Young children hospitalized for cannabis toxicity are increasingly exposed to high-concentration products (edibles, resins, vaping fluid) containing extremely high cannabinoid levels, leading to sedation, respiratory depression, and other adverse effects. Chronic adolescent use is associated with neurocognitive changes and cannabinoid hyperemesis syndrome.

Key Numbers

Products involved include edibles, resins, and vaping fluid with extremely high cannabinoid concentrations. Acute toxicity in young children: sedation, respiratory depression. Chronic adolescent toxicity: neurocognitive changes, cannabinoid hyperemesis.

How They Did This

Review of recent literature on THC pharmacokinetics, pharmacodynamics, developmental impacts, and presentations of acute and chronic cannabinoid toxicity in pediatric patients.

Why This Research Matters

Legalization has made high-potency cannabis products more accessible in households with children. The mismatch between these products (designed for adult tolerance) and pediatric vulnerability creates a growing emergency medicine challenge.

The Bigger Picture

The pediatric cannabis toxicity problem is a direct consequence of product design and packaging decisions in the legal cannabis market. Unlike with alcohol, many cannabis edibles resemble candy or food products attractive to children.

What This Study Doesn't Tell Us

Review-level evidence without pooled quantitative data. The specific incidence of pediatric exposures varies by state and over time. Not all product types are equally well-studied for pediatric effects.

Questions This Raises

  • ?Are child-resistant packaging regulations sufficient?
  • ?What are the long-term outcomes for toddlers with acute high-dose THC exposure?
  • ?Should product design regulations specifically address appeal to children?

Trust & Context

Key Stat:
High-potency products = child risk
Evidence Grade:
Rated moderate because this is a clinical review synthesizing recent literature from a relevant pediatric perspective.
Study Age:
Published in 2019. Cannabis product diversity and potency have continued to increase since.
Original Title:
Cannabinoid toxicity in pediatrics.
Published In:
Current opinion in pediatrics, 31(2), 256-261 (2019)
Database ID:
RTHC-01950

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What happens when a young child eats cannabis edibles?

High-concentration cannabis products can cause sedation, respiratory depression, and other serious adverse effects in young children, who are much more sensitive than adults due to their smaller body size.

Are edibles the main concern?

Edibles, resins, and vaping fluids are the products most commonly involved in pediatric hospitalizations because they contain extremely high cannabinoid concentrations and may resemble regular food or candy.

Read More on RethinkTHC

Cite This Study

RTHC-01950·https://rethinkthc.com/research/RTHC-01950

APA

Blohm, Eike; Sell, Peter; Neavyn, Mark. (2019). Cannabinoid toxicity in pediatrics.. Current opinion in pediatrics, 31(2), 256-261. https://doi.org/10.1097/MOP.0000000000000739

MLA

Blohm, Eike, et al. "Cannabinoid toxicity in pediatrics.." Current opinion in pediatrics, 2019. https://doi.org/10.1097/MOP.0000000000000739

RethinkTHC

RethinkTHC Research Database. "Cannabinoid toxicity in pediatrics." RTHC-01950. Retrieved from https://rethinkthc.com/research/blohm-2019-cannabinoid-toxicity-in-pediatrics

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.